Core Insights - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 1.69% [2] - Shareholders' profit attributable to the company was 172 million RMB, showing an increase of 11.33% year-on-year [2] - The basic earnings per share were 0.54 RMB [2] Business Focus - The company is concentrating on two main industries: nuclear medical health and irradiation applications [2] - It provides comprehensive solutions in nuclear medicine and radiotherapy, forming a "6+N" industrial layout centered around isotopes, nuclear pharmaceuticals, nuclear medical equipment, and irradiation applications [2] - The business scope includes research, manufacturing, and sales of isotopes, radioactive drugs, and radiation sources, as well as irradiation sterilization, material modification, and EPC services for irradiation devices [2]